A comprehensive microbiological safety approach for agarose encapsulated porcine islets intended for clinical trials
The use of porcine islets to replace insulin producing islet b cells, destroyed during the diabetogenic disease process, presents distinct challenges if this option is to become a therapeutic reality for the treatment of type 1 diabetes. These challenges include a thorough evaluation of the microbiological safety of the islets. In this study, we describe a robust porcine islet screening program that provides a high level of confidence in the microbiological safety of porcine islets suitable for clinical trials.
Xenotransplantation